Purpose: Acinar cell carcinoma is a rare tumor of the exocrine pancreas. Clinical features such
as prognostic information, survival, and treatment outcomes are unknown. We present the …

Purpose Biliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis
has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, …

Purpose: 2-Methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17β metabolite
that at pharmacologic doses exerts antimitotic and antiangiogenic activities. Studies with a …

Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal
growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). …

Background. The purpose of this study was to determine the maximum tolerated dose (MTD),
recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus …

Background Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will
relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of …

Introduction. Notch1 has been shown to be a tumor suppressor in neuroendocrine tumors (NETs).
Previous in vitro studies in NET cell lines have also suggested that valproic acid (VPA)…

Until recently, development of chemotherapeutic agents that target mitosis has centered on
inhibiting the mitotic spindle through interactions with microtubules. The taxanes, while …

Veliparib is a potent, orally bioavailable, poly (adenosine diphosphate-ribose) polymerase (PARP)
inhibitor that crosses the blood–brain barrier and has been shown to potentiate the …

Background We recently reported an acceptable safety and pharmacokinetic profile of
depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and …